Beren Therapeutics
Developer of therapeutics for conditions characterized by defective cholesterol trafficking.
About
Technology stack
detected 2026-06-12“Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
What does Beren Therapeutics do?
Beren Therapeutics is a biotechnology company focused on developing novel therapeutics for diseases associated with defective cholesterol trafficking. Their approach aims to address a range of conditions where the body's ability to manage cholesterol is impaired.
How much funding has Beren Therapeutics raised?
Beren Therapeutics has raised a total of $10M in funding. The most recent round on record is Seed.
Where is Beren Therapeutics headquartered?
Beren Therapeutics is headquartered in Thousand Oaks, California, USA.
When was Beren Therapeutics founded?
Beren Therapeutics was founded in 2017.
What industry does Beren Therapeutics operate in?
Beren Therapeutics operates in Biotech, Biotechnology, Healthcare, Pharmaceuticals, Drug Discovery, HealthTech.
What is Beren Therapeutics's current status?
Beren Therapeutics's current operating status is: Inactive.